About Domainex
Domainex is a Healthcare company based in Cambridge (United Kingdom) founded in 2001. Drug discovery CRO company for epigenetic research and inflammatory diseases. Domainex has raised $4.97 million across 6 funding rounds from investors including YFM Equity Partners, Wellcome and Longbow Capital. The company has 93 employees. Domainex offers products and services including Integrated Drug Discovery Services, Medicinal Chemistry, Structural Biology, and Assay Development. Its focus areas include Biopharma Outsourcing, CRO and Drug Discovery. Its legal entity is DOMAINEX LIMITED. Its competitors include CatSci and Concept Life Sciences; 1 of its 2 listed competitors has raised funding.
Company details
Domainex is a drug discovery CRO that develops small molecule compounds for epigenetic research and inflammatory diseases. Domainexs services include proprietary platforms based services such as Combinatorial Domain Hunting (for structural studies and assay development) and LeadBuilder (virtual and fragment-based approaches to hit identification), medicinal chemistry and computational chemistry services, protein expression capabilities and cell-based and biochemical assay development offering. The company had won the 1.4m Biomedical Catalyst Award for the success of its Lead Compound in Pre-clinical Model of COPD. Domainex merged with NCE Discovery in 2007 to form a drug discovery company focussed on nucleotide triphosphate (NTP)-dependent proteins. The companys clientele includes UCB, FORMA Therapeutics, St Georges University, The Institute of Cancer Research and Auspherix. Domainex claims that it has delivered on an average one candidate drug per year in the six years since 2010.
- Headquarters Cambridge, United Kingdom
- Employees 93
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website domainex.co.uk
- Social LinkedIn X Facebook
- Legal Name Domainex Limited
- Date of Incorporation 10 Dec, 2001
- Jurisdiction SAFFRON WALDEN, ENGLAND
- Annual Revenue$15.49 M (USD)19as on Dec 31, 2022
- Net Profit$1.85 M (USD)8as on Dec 31, 2022
- Total Equity Funding$4.97M (USD)
in 6 rounds
- InvestorsYFM Equity Partners
& 4 more
- Employee Count93
Products & Services of Domainex
Domainex offers a comprehensive portfolio of products and services, including Integrated Drug Discovery Services, Medicinal Chemistry, Structural Biology, and Assay Development.
Comprehensive platform for hit to lead optimization in pharmaceuticals
Design and synthesis of compounds for drug development
Techniques like X-ray crystallography for protein analysis
Creation of tests for evaluating drug candidates
Funding Insights of Domainex
Domainex has successfully raised a total of $4.97M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $4.97M
- Total Rounds 6
- First Round $711,787
(Jun 2007)
- Investors Count 5
All 6 funding rounds of Domainex with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2016 | Grant | – | – | ||
| Dec 2012 | $2.3M | Series A | – | – | |
| Nov 2011 | $398,380 | Grant | – | – | – |
| Feb 2010 | Series A | – | – | ||
| Apr 2008 | $1.96M | Series A | – | – | |
| Jun 2007 | $711,787 | Seed | – | – |
5 investors in total: 5 institutional.
Investors in Domainex
Domainex has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include YFM Equity Partners, Wellcome and Longbow Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| longbow.co.uk | ||||
| bflap.co.uk | ||||
| takedaventures.com | ||||
Private equity firm focused on multiple sectors | 1982 | yfmep.com | Leeds, United Kingdom | |
Wellcome is a global charitable foundation focused on health research. | wellcome.ac.uk | London, United Kingdom |
Investor details for Domainex
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Domainex
30 people are tracked at Domainex (7 in leadership, 6 in board & advisors, 17 in team); the tracked headcount is 93.
| Name | Role | Group |
|---|---|---|
Scott Martin | Head, Bioanalytical Sciences | Leadership |
Andrew Ratcliffe | Head, Chemistry | Leadership |
Trevor Askwith | Head, Biology | Leadership |
Philip Fallon | Deputy Head, Chemistry | Leadership |
Tom Mander | CEO | Leadership |
Natalie Winfield (nee Saunders) | Executive Vice President, Commercial Operations | Leadership |
Andrea Fuller (MCIPD) | Human Resources Director | Leadership |
Frank Bury | Director | Board & advisors |
Judith Hills | Director | Board & advisors |
Steve Harris | Deputy Chairman | Board & advisors |
Eddy Littler | Executive Chairman | Board & advisors |
Edward Beckett | Director | Board & advisors |
Laurence Pearl | Director | Board & advisors |
Ray Boffey | EVP, Medicines Research & Strategic Alliances | Team |
Tifelle Reisinger | Australian Business Strategist | Team |
Paolo Ricci | Principal Scientist In Medicinal Chemistry | Team |
Philip Rawlins | Group Leader | Team |
Jason Pembroke | Bioanalytical Group Leader | Team |
Jonathan Powell | Group Leader, Chemistry | Team |
Hannah McNeil | Senior Commercial Operations Scientist | Team |
10 more people are available in the full profile.
Complete people profiles for Domainex
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Domainex
3 dated milestones of Domainex across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Domainex is founded.
- Funding First funding round of $712K.
- Funding Latest funding round, Grant,.
Competitors of Domainex
Domainex has 2 listed competitors in our database, 1 of them funded. They include CatSci and Concept Life Sciences.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| catsci.com | 2010 | Cardiff, United Kingdom | $5.89M | 63 | Drug discovery services are provided to pharmaceutical clients worldwide. | |
| conceptlifesciences.com | 2014 | Manchester, United Kingdom | International laboratory testing and consultancy in life sciences are offered. |
Detailed competitors of Domainex
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Domainex
The website of Domainex (domainex.co.uk) receives about 8.6K visits a month and ranks #2,858,284 among all websites worldwide, #3,827 in Biotechnology and Pharmaceuticals.
- Monthly visits8.6K
▲ 15.6% vs previous month
- Unique visitors3.2K
per month
- Global rank#2,858,284
among all websites
- Category rank#3,827
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.6
- Average visit43 sec
- DevicesDesktop 30% · Mobile 70%
Websites whose visitors overlap most with Domainex. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| idifarma.com | 100% | View details | |||
| worldwide.com | 83% | 89.1K | #546,596 | View details | |
drugtargetreview.com | drugtargetreview.com | 50% | #387,873 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Domainex
Complete news archive for Domainex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Domainex
Domainex was founded in 2001 and raised its 1st funding round 6 years after it was founded.
Domainex is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Domainex is a funded company, having raised a total of $4.97M across 6 funding rounds to date. The company's 1st funding round was a Seed of $711.79K, raised on Jun 2007.
Domainex has 93 employees.
Annual revenue of Domainex is $15.49M as on Dec 31, 2022.
Domainex is a drug discovery CRO that develops small molecule compounds for epigenetic research and inflammatory diseases. Domainexs services include proprietary platforms based services such as Combinatorial Domain Hunting (for structural studies and assay development) and LeadBuilder (virtual and fragment-based approaches to hit identification), medicinal chemistry and computational chemistry services, protein expression capabilities and cell-based and biochemical assay development offering. The company had won the 1.4m Biomedical Catalyst Award for the success of its Lead Compound in Pre-clinical Model of COPD. Domainex merged with NCE Discovery in 2007 to form a drug discovery company focussed on nucleotide triphosphate (NTP)-dependent proteins. The companys clientele includes UCB, FORMA Therapeutics, St Georges University, The Institute of Cancer Research and Auspherix. Domainex claims that it has delivered on an average one candidate drug per year in the six years since 2010.
Domainex's top competitors include Concept Life Sciences and CatSci.
Domainex offers Integrated Drug Discovery Services, Medicinal Chemistry, Structural Biology, and Assay Development.
Domainex has 5 investors. Key investors include YFM Equity Partners, Wellcome, Longbow Capital, Bury Fitzwilliam-Lay And Partners, and Takeda Ventures.
Domainex operates through Domainex Limited.